Comparing acquired angioedema with hereditary angioedema (type I/II)

The journal Clinical and Experimental Immunology has published an article about comparing acquired angioedema with hereditary angioedema (type I/II). Icatibant is approved for hereditary angioedema with C1 inhibitor deficiency type I/II (C1-INH-HAE type I/II) and has shown promise in treatment of angioedema due to acquired C1 inhibitor deficiency (C1-INH-AAE). Data from the Icatibant Outcome Survey was analyzed to evaluate effectiveness of icatibant in the treatment of patients with C1-INH-AAE and compare disease characteristics with those with C1-INH-HAE type I/II. The full-text article you can find here.